Skip to main content
. 2024 Jun 1;29(9):e1201–e1208. doi: 10.1093/oncolo/oyae097

Figure 1.

Figure 1.

Clinical responses to trastuzumab and docetaxel in patients with advanced HER2-positive extramammary Paget’s disease. (A) Waterfall plot: relative change (%) in the sum of the diameters of target lesions at the primary endpoint after 3 cycles compared with baseline. (B) Estimated progression-free survival (left panel) and overall survival (right panel) (Kaplan-Meier plots).